Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows

Adding GEN-1 to Standard Chemotherapy Halts Advanced Ovarian Cancer Progression, Phase 1b Trial Shows
A combination of Celsion’s DNA-based immunotherapy GEN-1 and standard chemotherapy halted disease progression in women with stage III/IV ovarian cancer eligible for surgery, according to results of a Phase 1b trial. The findings also revealed that all patients on the highest GEN-1 dose had complete tumor removals, and approximately 86% of patients had a complete or partial

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *